FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OIVID APPROVAL									
OMB Number:	3235-0287								
Estimated average I	ourden								
haura nor roonanaa	0.5								

OMB ADDDOMAI

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or	Section	on 300	(n) of the	nvesti	ment C	company Act	of 1940								
Name and Address of Reporting Person* Ramasastry Saira						2. Issuer Name and Ticker or Trading Symbol SANGAMO THERAPEUTICS, INC SGMO								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>Kamasasti y Sana</u>				SC	X Direct									or		10% Ov	vner			
(Last) (First) (Middle)				_										Officer below)	(give title		Other (s below)	specify		
, ,	`	HERAPEAUTIC	` ,			3. Date of Earliest Transaction (Month/Day/Year)														
			,,,,,,,		12	12/17/2020														
7000 MARINA BLVD						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
(Street)														Line) X Form filed by One Reporting Person						
BRISBA	NE C	A	94405											Λ	Form filed by More than One Reporting					
					-									Person						
(City)	(S	tate)	(Zip)																	
		Tab	le I - N	Non-Der	ivativ	e Sec	curit	ties A	cquire	d, D	isposed o	f, or B	enefici	ally (Owned					
1. Title of S	Security (Inst	tr. 3)		2. Transac	tion	Execution Date,					Acquired (A) or			5. Amount of Securities				7. Nature of Indirect		
				(Month/Da	y/Year)			·			Disposed Of (D) (Instr. 3, 4 and			Benefic		ally	(D) o	r Indirect	Beneficial Ownership	
								y/ rear)	0)	-		(4) ==		Re _l		wned Following eported ansaction(s)			(Instr. 4)	
									Code		Amount	(A) or (D)	Price			and 4)				
Common Stock 12/17/202			2020	20		M		10,000	A	\$5.9	\$5.99		25,000(1)		D					
Common Stock 12/17/202			2020				S		10,000	D	\$13.27	2747 ⁽²⁾ 15,000 ⁽¹⁾				D				
		-	Table I								posed of,				wned					
					1	calls	_		1		converti			_						
Derivative Conversion Date Exe Security or Exercise (Month/Day/Year) if a			if any	ition Date, Tra		ansaction of de (Instr. Se Ad (A Di of		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		ty Or	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owner Form Direct or Ind (I) (Ins	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
													Amou							
									Date		Expiration		Numb of							
					Code	٧	(A)	(D)	Exerc	isable	Date	Title	Share	5						
Stock Option (Right-to- Buy)	\$5.99	12/17/2020			M			10,000	(3	3)	06/13/2026	Commo	n 10,00	00	\$0.00	0		D		

Explanation of Responses:

- 1. Includes 10,000 shares of common stock subject to restricted stock units ("RSUs") granted on May 15, 2020. The RSUs will fully vest on the earlier of (x) May 15, 2021 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service through such dates as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended") and subject to acceleration as defined in the 2018 EIP, as amended.
- 2. The price reported is a weighted average price. The shares were sold at prices ranging from \$13.26 to \$13.32 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- 3. The option was immediately exercisable for all option shares, but shares purchased under the option were subject to certain repurchase rights by the Issuer upon the cessation of the Reporting Person's service on the Board of Directors of the Issuer. The shares subject to each option vested in monthly installments upon completion of each month of Board service over a three year period measured from the date of grant.

Remarks:

/s/ Matthew Colvin, Attorneyin-Fact for Saira Ramasastry

12/18/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.